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Deﬁnitive radiotherapy for unresected adenoid cystic carcinoma of the trachea
E. González, V. Díaz, E. Munive, L. Gutierrez, L. Díaz, I. Villanego, M. Salas
Hospital Universitario Puerta del Mar, Oncología Radioterápica, Spain
Adenoid cystic carcinoma (ACC) is a rare malignancy that usually originates in the salivary glands of the head and neck but
has rarely been known to originate in the trachea. This tumor has a tendency for local and distant recurrences. The present
report describe a 66 years old female with unresectable ACC of the trachea who was treated with deﬁnitive radiotherapy (RT).
She presented humid cough and dyspnoea. A chest CAT scan and bronchoscopy were performed, showing a exophytic mass in
the in the middle third tracheal, occupying 85% of the tracheal lumen, with a diameter of 4 cm. Histological conﬁrmation was
obtained by biopsy. Endoprosthesiswas required. The patientwas treatedwith deﬁnitive three-dimensional conformal radiother-
apy (3DCRT), using photons and a dose of 60Gy. Esofagitis G1was appeared as acute toxicity and clinical and radiological response
were observed at 11 months after treatment. The surgical resection is the mainstay of treatment of tracheal adenoid cystic carci-
noma, tumor size, location, and patient comorbidities may preclude surgery, and the optimal nonsurgical management remains
undeﬁned. In the absence of locoregional lymph node metastases, the highly conformal radiotherapy is considered as alternative
treatment. The results of radiotherapy with photons for advanced ACC have been reported to be suboptimal in the setting of
inoperable, not completely resected and recurrent tumors. Nevertheless postoperative radiotherapy have been show to have a
favorable impact on local control rates and survival rates in advance stages of ACC: In our case we obtained a favourable clinical
and radiological response with acceptable toxicity performing deﬁnitive RT in unresectable tracheal adenoid cystic carcinoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.305
Hyperfractionated RT-QT treatment in small cell lung carcinoma
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Introduction. The standard treatment in small cell lung cancer limited disease (SCLC LD) involves chemotherapy (CT) based in plat-
inum+ thoracic radiotherapy+prophylactic cranial irradiation (IPC). In patients <70 years with good ECOG, chemo-radiotherapy
treatment hyperfractionated (RTHF) concomitant early is considered the better treatment option for both local control and
long-term survival.
Objective. To analyze toxicity, response and survival in our series.
Material and methods. Patients diagnosed to SCLC LD between August’09 and June’12, treated with CT based in platinum+RTHF
concomitant according Turrisi scheme. Inclusion criteria were: <70 years, PS 0–1, good respiratory function, absence of signiﬁcant
comorbidity and socio-family support.
Results. We analyzed 12 patients (7 men and 5 women) with a median age of 62.5 years (range 43–73). Six patients received
concomitant QT-RTHF early on (with the ﬁrst 2 cycles), the other 6 was late. 45Gy were given 1.5Gy for session, two sessions
per day separated by 6–8h. No prophylactic nodal irradiation was performed. Patients received 4–6 cycles of chemotherapy and
then, except one patient who refused treatment, received IPC (36Gy at 2Gy per session). Both pulmonary and esophageal toxicity
was acceptable. Mean follow-up was 19.45 months (range 7–33 months). In 2 patients were lost follow-up, four have died of the
disease and 6 remain alive free of disease with a mean of 15.5 months (range 7–22).
Conclusions. QT-RTHF has shown better results in treating SCLC LD, although the long-term survival remains low (5–10%). 70% of
patients free of disease after 2 years do not fall, according to the literature. We will have to see the evolution of our patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.306
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Introduction. Hypoxia is one of themain causes of the failure to achieve local control using radiotherapy. This is due to the increased
radioresistance of hypoxic cells. 18F-ﬂuoromisonidazole (18F-FMISO)-PET is a non-invasive imaging technique that can assist in
the identiﬁcation of intratumor regions of hypoxia. We initiated a phase I trial to examine the feasibility of 18F-FMISO PET/CT
guided IMRT with the goal of maximally escalating the dose to radioresistant hypoxic zones concurrent with chemotherapy in
stage III lung cancer patients.
Objective. This work investigates the feasibility of dose painting to these hypoxic regions in the patients included in the ﬁrst step
of dose escalation study.
Materials and methods. Four patients were included. The CT simulation, ﬂuorodeoxyglucose (18F-FDG) PET/CT, and18F-FMISO
PET/CT scans were co-registered using the same immobilization methods. A ﬁrst planning target volume (PTV-FDG) was deﬁned
by clinical examination and available imaging studies, including 18F-FDG PET/CT. Regions of elevated 18F-FMISO uptake within
S264 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S259–S274
the tumor were targeted for an IMRT boost. In this step, doses to PTV-FDG were 70.2Gy; 1.8Gy/day and to PTV-FMISO were
76.05Gy; 1.95Gy/day. Treatment plans were generated without exceeding the normal tissue tolerance.
Results. The GTV-FDG was highly variable and ranged between 17.91 cm3 and 248.58 cm3 (median 94.82±104). The GTV-FMISO
ranged between 0.57 cm3 and 37.55 cm3 (median 12.26±16 cm3), representing 13% of GTV-FDG .The GTV-FDG and GTV-FMISO
ranged between 17.24% and 100% (median 76.25±39%). In the majority of cases the hypoxic subvolume was diffusely dispersed
in multiple areas of the whole PTV. With a median follow-up of 10 months there was not any local recurrence.
Conclusion. 18F-FMISO-PET imaging could be used for a hypoxia-directed intensity-modulated radiotherapy approach in lung
cancer. Dose escalation was shown to be feasible under the constraint of limiting normal tissue doses. In the majority of cases
the hypoxic subvolume is within the volume deﬁned by 18F-FDG PET/CT.
http://dx.doi.org/10.1016/j.rpor.2013.03.307
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Purpose. The aim of this study was to evaluate the effects of 4DCT and FDG-PET/CT registration on treatment planning in lung
cancer patient and to compare the results achieved with those obtained with the PTV margins currently used in 3DCT.
Material and methods. Five NSCLC patients stage I-II with contraindication to surgery underwent radiotherapy. The median age
was 74.8±4.8 y.o. Histology was 2 squamous, 2 adenocarcinoma and one NSCLC. Patients were imaged using 3DCT (slowCT/4s)
free breathing, 4DCT free breathing 10 phases and FDG-PET/CT all three performed on the same day in the treatment position
and co-registered in order to allow comparisons. PET images were interpreted by a nuclear medicine physician. A radiation
oncologist contoured GTVs on 3DCT and all 10 phases of the 4DCT for each patient. PET positive GTVs were countored using 50%
SUVmax. For 3DCT images a CTV-3D was generated from GTV-3Ds by adding up 5mm and afterwards PTV-3D was generated
from CTV-3D with a margin of 1–1.5 cm. In 4DCT the ITV was build encompassing the PET-GTVs and the GTVs delineated in all
10 phases. PTV-4D was created by expanding the ITV with a 7mm margin. Organ at risk (OARs) were countored. Treatment plans
were designed and calculate for both PTVs.
Results. DHV shows a mean volume of the PTV-3D of 284±96 cm3, which was greater than the mean PTV-4D volume, which was
160±54 cm3. The mean decrease of the PTV volume obtained with 4DCT was 123±43 cm3, which represents a reduction of 42%.
The V20 were 11.22±3.1% for 3DCT and 8.5±4.7% for 4DCT. V20 improved with 4DCT by only 2,7% but the mean lung dose was
decreased by 21% for ipsilateral lung and 26% for contralateral. No signiﬁcant differences were found for the rest of OARs.
Conclusion. 4DCT and PET/CT based treatment planning is feasible and it provides signiﬁcant dosimetric advantages over 3DCT,
such as allows personalized and smaller PTV volumes, improving mean lung doses and reducing intraobserver variability in PTV
delineation.
http://dx.doi.org/10.1016/j.rpor.2013.03.308
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Purpose. To report acute toxicity, quality of life (QOL) and dosimetric parameters in radiation treatment of advanced lung cancer
with Volumetric Modulated Arc Therapy (VMAT) – RapidArc and IGRT.
Methods. Fifty-ﬁve consecutive patients, with inoperable tumour, were treated with VMAT to a median dose of 67.4Gy (range
60–74Gy). Treatment delivery was performed with two partial or total arcs. IGRT was made with daily CBCT. Acute toxicity was
scored following RTOG criteria and QOL with EORTC-QLQ-C30 and EORTC-QLQ-LC13.
Results. From a dosimetric point of view, VMAT plan fulﬁlled all our dose constraints. PTV volume median: 333.03 cm3
(87.50–1442.66 cm3). The mean dose coverage 95% of PTV volume: 98.66±1.03% lung: V5=60.01±15.21%, V10=42.44±2.32%,
V20=21.22±6.33%, mean lung dose (MLD) was 13.87±3.63Gy; esophagus V66=3.76±5.26%, V50=20.01±14.58%,
V35=32.80±15.55% and mean esophagus dose: 24.14±8.8Gy; spinal cord D1%=32.85±7.96Gy; heart V45=2.79±4.42%.
Acute toxicities were 1 patient with grade 3 esophageal toxicity, 2 with grade 2 and 52 with grade 1. No other toxicities were
observed. QLQ-C30 showed between start to end of the treatment: cough and haemoptysis improved and dysphagia worsened.
No changes in dyspnea were observed. QLQ-LC13: Physical and role functioning improved while asthenia and appetite loss
worsened.
Conclusions. VMAT outcomes are very promising and toxicity rates were mild for inoperable lung cancer. Further follow-up is
required to assess late toxicity and disease control.
http://dx.doi.org/10.1016/j.rpor.2013.03.309
